Related Experiment Video
Updated: Sep 23, 2025
Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies
Published on: August 11, 2023
Characteristics of oncology podcasts: Attitudes, speakers, conflicts
Emma Greenstreet Akman1, Kerrington Powell2, Alyson Haslam3
1School of Medicine, University of California, San Francisco, CA, USA.
Objective:
To systematically appraise the content within oncology podcasts and the individuals who speak on them.
Design:
A cross-sectional study.
Setting:
We obtained a list of 33 current podcasts with substantial oncologic content through queries of predetermined search terms on the Apple Podcast Platform.
Participants:
98 oncology-related podcast episodes.
Main Outcomes:
The perceived attitude of the episode with predetermined categories including "Neutral," "Favorable," or "Negative," the number of conflicts of interest verbally disclosed by individuals featured on oncology podcasts, and the prevalence of general payments among featured physicians.
Results:
Among 33 oncology podcasts, the median number of episodes was 81 (IQR: 25-129). Ninety-seven percent (n = 32/33) of the podcasts included guests. The median episode run time was 26:50 min (IQR: 18:00 - 41:75). Among the 98 episodes assessed, 47% of episodes (n = 46/98) mentioned oncologic drugs, of which 57% (n = 26) had a neutral disposition, 37% (n = 17) had a favorable disposition and 7% (n = 3) were negative. Across 98 episodes, we identified 194 featured individuals, of which 65% (n = 126) had a medical degree (MD), and 85% (n = 107/126) of these physicians received at least one general payment. Further, 83% (n = 105/126) of physicians did not disclose payments.
Conclusions And Policy Summary:
Within oncology-related podcasts, the majority of conversations about oncologic drugs are perceived as either favorable or neutral, and a majority of individuals featured on podcasts do not disclose conflicts of interest, highlighting potential opportunities for improvement, including the need for standardization of financial conflict of interest disclosure.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Ethical Issues
Ethical Concerns in Healthcare:
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy